This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The costing was carried out on the same patient sample as that used in the effectiveness study, but it is not clear whether it was carried out prospectively or retrospectively.
Study sample
313 patients with LC were enrolled on to the screening programme (193 were men and 120 women). The mean age was 56.8 years (SD 11.97 ). The average age was 61.8 years (SD 10.3 3.8% were in Child-Pugh class C; 82.4% had AFP less than 20ng/dl; and 17.6% had AFP greater than 20ng/dl. When the study finished, 111 patients were still under surveillance, of whom 61 had developed HCC, and the others had died, were lost to follow-up or had entered category 4 above (see Study Population).
The patients in the surveillance programme were compared with 104 patients who had already been diagnosed with HCC. Their average age was 63.8 years (SD 11.1). No power calculations were carried out.
Study design
This was a non-randomised trial with concurrent controls, carried out in a single centre. The method of selection of patients per group was not stated. Patients were followed up until December 1997 unless they died or were lost to follow-up (24 patients).
Analysis of effectiveness
The analysis was based on treatment completers only. The following health outcomes were used:
(1) number and size of HCC nodules detected;
(2) eligibility of patients, detected with HCC, for treatment; and
(3) survival of patients with HCC.
In terms of health status, age and sex ratio the control group patients differed from those in the surveillance group who turned out to have HCC. The differences in health status (in terms of HCC), were shown to be statistically significant. The authors did not compare the characteristics of the whole surveillance group with those of the control group.
Effectiveness results
The effectiveness results were as follows: However, it appears that this did not control for tumour staging, which was shown by multivariate analysis to have a coefficient with p<0.001. Also there appeared to be no statistically significant independent contribution of treatment group, as evidenced by the statement "if tumour staging was removed from the analysis, inclusion in the surveillance programme became significantly associated."
Clinical conclusions
The effectiveness measures used showed that surveillance had patients with statistically significantly fewer lesions, which were, on average, smaller, and that more patients who had undergone surveillance were eligible for treatment. It was also shown that those with HCC lived statistically significantly longer if they had been surveyed. Finally, surveillance seemed to have no independent, statistically significant effect on the whole group, after controlling for staging.
Modelling
Survival was calculated using life tables by the method of Kaplan Meyer. A multivariate model was used to control for variables associated with survival using input variables chosen by first using a univariate model. However, the multivariate model does not seem to have been used to control for prognostic factors for HCC patients only.
Measure of benefits used in the economic analysis
The measures of benefits used were number of treatable cases of HCC detected and number of years of life saved.
Direct costs
The following unit costs were given: measuring APF; ultrasound scan; computed tomography; echo guided biopsy;
transarterial chemoembolisation (TACE);
